TY - JOUR
T1 - Does Metformin Increase Paraoxonase Activity in Patients with the Metabolic Syndrome? Additional Data from the MEFISTO Study
AU - Meaney, Eduardo
AU - Sierra-Vargas, Patricia
AU - Meaney, Alejandra
AU - Guzmán-Grenfell, Martín
AU - Ramírez-Sánchez, Israel
AU - Hicks, Juan Jose
AU - Olivares-Corichi, Ivonne
AU - Ceballos, Guillermo
PY - 2012/6
Y1 - 2012/6
N2 - In a subanalysis on the metformin, arterial function, intima-media thickness, and nitroxidation in the metabolic syndrome (MEFISTO)8 (an open-label fashion, with 1 year of 850 mg daily of metformin) subjects' samples, we measured the paraoxonase 1 (PON1) activity in 39 patients that finished the study and relate values with high density lipoprotein (HDL). The comparative PON1 activities at the beginning and at the end of the study were 5.528 ± 0.588 and 4.743 ± 0.619 nmol/mg protein/min (NS) for control group and 3.229 ± 0.403 and 5.135 ± 0.585 nmol/mg protein/min (p < 0.02) for the metformin group. Our data showed an enhance of PON1 activity in patients with metabolic syndrome treated with metformin, although in them, the raise of HDL concentration was less than control patients, suggesting that the increase in quality (measured here as PON1 activity) could be at least as important as an increase in its concentration. Our results point out that there is a relationship among PON1 activity and the reduction of carotideal intima-media thickness.
AB - In a subanalysis on the metformin, arterial function, intima-media thickness, and nitroxidation in the metabolic syndrome (MEFISTO)8 (an open-label fashion, with 1 year of 850 mg daily of metformin) subjects' samples, we measured the paraoxonase 1 (PON1) activity in 39 patients that finished the study and relate values with high density lipoprotein (HDL). The comparative PON1 activities at the beginning and at the end of the study were 5.528 ± 0.588 and 4.743 ± 0.619 nmol/mg protein/min (NS) for control group and 3.229 ± 0.403 and 5.135 ± 0.585 nmol/mg protein/min (p < 0.02) for the metformin group. Our data showed an enhance of PON1 activity in patients with metabolic syndrome treated with metformin, although in them, the raise of HDL concentration was less than control patients, suggesting that the increase in quality (measured here as PON1 activity) could be at least as important as an increase in its concentration. Our results point out that there is a relationship among PON1 activity and the reduction of carotideal intima-media thickness.
KW - Carotid intima-media thickness
KW - HDL cholesterol
KW - Metabolic syndrome
KW - Metformin
KW - Paraoxonase
UR - http://www.scopus.com/inward/record.url?scp=85027937260&partnerID=8YFLogxK
U2 - 10.1111/j.1752-8062.2012.00391.x
DO - 10.1111/j.1752-8062.2012.00391.x
M3 - Artículo
C2 - 22686204
SN - 1752-8054
VL - 5
SP - 265
EP - 268
JO - Clinical and Translational Science
JF - Clinical and Translational Science
IS - 3
ER -